October 3, 2011 —The American Society of Echocardiography (ASE) has published guidelines for new applications for echocardiography in the neonatal intensive care unit (NICU). An expert consensus statement, “Targeted Neonatal Echocardiography in the Neonatal Intensive Care Unit: Practice Guidelines and Recommendations for Training,” has been published in the October 2011 issue of JASE, the ASE’s monthly journal, and is also available online at: www.asecho/guidelines. The document defines the scope and appropriateness of echocardiography in the NICU and defines standards for both the echocardiographic examination and the individuals who perform and interpret these studies.

September 30, 2011 — Vision RT announced it has increased sales of AlignRT, its 3-D imaging platform, to several advanced TrueBeam facilities in the United States in recent months.

September 30, 2011 – Siemens Healthcare returns to the Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 2-6 in Miami, with a broad range of solutions that multiply chances – for life. At this year’s booth (#203), Siemens will demonstrate its strong commitment to battling cancer with a portfolio that covers the spectrum of oncology care, with a particularly strong focus on diagnostic oncology imaging in in-room and outside-the-room imaging as well as in radiation therapy.

September 30, 2011 – ViewRay Inc. will present potential applications for magnetic resonance imaging (MRI)-guided radiotherapy at the annual meeting of the American Society for Radiation Oncology (ASTRO) Oct. 2-4 in Miami Beach, Fla., with software demonstrations in booth #865. The company's new research radiation therapy system is being developed to feature a patented combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI). The system is being designed to let radiation oncologists see what they're treating, while they're treating.

September 28, 2011 – Calypso Medical Technologies Inc., developer of real-time localization technology used for precise tumor tracking, announced that the U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval for its clinical study evaluating real-time tracking of lung cancer tumors during radiation delivery. Patient enrollment is planned at Washington University in St. Louis, and the Cancer Treatment Centers of America in Tulsa, Oklahoma. Investigators in the United States will implant three anchored Beacon transponders in patients’ lungs and use the Calypso System to precisely track tumor location and movement during lung cancer radiation therapy.